Sergey Yagoda

Alkermes, Inc.

Alkermes, Inc. (Employment)

Poster(s):

• (P-313) Utilizing a Structured Benefit-risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder